Over 80% of healthcare insurances are highly concerned about how to cover new medical innovations. There is a risk of uncontrolled cost increase, with an estimated budget impact of $ 300BN in the next years, just for these Cell & Gene therapies alone.*(FocUS)
Lyfegen helps you address the risk of covering new medical innovations by enabling value-based contracting, at scale. The unique combination of our expertise & data analytics platform increases your affordability to provide optimal coverage for your population.
Let us show you how.
Read our case study to see how Lyfegen is helping cancer patients access innovative drugs with a value-based contract.
We help you to increase your value for money by reducing risk of covering medical innovations, addressing their efficacy and safety uncertainty and avoid wasted spend.
With the experience in designing, implementing, and tracking over 120 value-based contracts, Lyfegen’s knowledge is undisputable. Covering multiple disease areas, from public to private healthcare payers, and using our AI data analytics software, we break down the complexity of value-based contracts for you to implement the right type of agreements.
Book a demo
With privacy and data protection embedded in our identity, our technology was created with privacy-by-design principles. We are GDPR and HIPAA compliant and ISO 27001 (Information Security Management) and ISO 9001 (Quality management) certified. We take great care to ensure that our platform is 100% secure for our customers.
